Bayesian Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Bayesian Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-35,814	Closed	-$1.58M	–	863
2025 Q1	$1.58M	Buy	+35,814	New	+$1.65M	0.26%	113
2024 Q4	–	Sell	-19,414	Closed	-$622K	–	987
2024 Q3	$622K	Buy	19,414 +10,600	+120%	+$396K	0.07%	330
2024 Q2	$332K	Buy	+8,814	New	+$371K	0.04%	484
2024 Q1	–	Sell	-6,398	Closed	-$234K	–	1108
2023 Q4	$234K	Buy	+6,398	New	+$167K	0.02%	565

Other funds holding SWTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Bayesian Capital Management's SWTX Position: Q2 2025 in Review

Bayesian Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 35,814 shares — an estimated $1.58M sold.

Bayesian Capital Management first reported a position in SWTX in Q4 2023 and held it in 4 quarters. The position peaked at $1.58M in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Bayesian Capital Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Bayesian Capital Management sold 35,814 SpringWorks Therapeutics shares in Q2 2025, an estimated $1.58M.
Bayesian Capital Management first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 4 quarters.
Bayesian Capital Management's SpringWorks Therapeutics position peaked at $1.58M in Q1 2025.
223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.